Eye : Impact Factor & More
eISSN: 1476-5454pISSN: 0950-222X
Share this on:
Key Metrics
CiteScore 
5.9
H-Index
113
Impact Factor
< 5
SJR
Q1Ophthalmology
SNIP
2.08
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Eye
Eye Journal Specifications
| Overview | |
| Publisher | SPRINGERNATURE |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1987 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Eye ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Eye
Exploring the mixed marketing authorisation pathway: a case study in ophthalmology.
- 8 Aug 2026
- Eye (London, England)
Can large language models accurately triage oculoplastic referrals?
- 7 Aug 2026
- Eye (London, England)
Photic retinal injury: Time to move beyond case reports-A PRISM Study Group perspective.
- 7 Aug 2026
- Eye (London, England)
Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial.
- 7 Aug 2026
- Eye (London, England)
Ophthalmic and psychiatric health: the overlooked connection between ocular diseases and mental disorders.
- 7 Aug 2026
- Eye (London, England)
Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice.
- 7 Aug 2026
- Eye (London, England)
Exploring the mixed marketing authorisation pathway: a case study in ophthalmology.
- 8 Aug 2026
- Eye (London, England)
Can large language models accurately triage oculoplastic referrals?
- 7 Aug 2026
- Eye (London, England)
Photic retinal injury: Time to move beyond case reports-A PRISM Study Group perspective.
- 7 Aug 2026
- Eye (London, England)
Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial.
- 7 Aug 2026
- Eye (London, England)
Ophthalmic and psychiatric health: the overlooked connection between ocular diseases and mental disorders.
- 7 Aug 2026
- Eye (London, England)
Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice.
- 7 Aug 2026
- Eye (London, England)
FAQs on Eye
How long has Eye been actively publishing? 
What is the publishing frequency of Eye?
How many articles did Eye publish last year?
What is the eISSN & pISSN for Eye?
What is Citescore for Eye?
What is the H Index for Eye ?
What is SNIP score for Eye?
What is the SJR for Eye?
Who is the publisher of Eye?
